TY - JOUR T1 - Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review JF - European Respiratory Journal JO - Eur Respir J SP - 1763 LP - 1775 DO - 10.1183/09031936.00193413 VL - 43 IS - 6 AU - Tadayuki Tanimura AU - Ernesto Jaramillo AU - Diana Weil AU - Mario Raviglione AU - Knut Lönnroth Y1 - 2014/06/01 UR - http://erj.ersjournals.com/content/43/6/1763.abstract N2 - In order to inform the development of appropriate strategies to improve financial risk protection, we conducted a systematic literature review of the financial burden of tuberculosis (TB) faced by patients and affected families. The mean total costs ranged from $55 to $8198, with an unweighted average of $847. On average, 20% (range 0–62%) of the total cost was due to direct medical costs, 20% (0–84%) to direct non-medical costs, and 60% (16–94%) to income loss. Half of the total cost was incurred before TB treatment. On average, the total cost was equivalent to 58% (range 5–306%) of reported annual individual and 39% (4–148%) of reported household income. Cost as percentage of income was particularly high among poor people and those with multidrug-resistant TB. Commonly reported coping mechanisms included taking a loan and selling household items. The total cost of TB for patients can be catastrophic. Income loss often constitutes the largest financial risk for patients. Apart from ensuring that healthcare services are fairly financed and delivered in a way that minimises direct and indirect costs, there is a need to ensure that TB patients and affected families receive appropriate income replacement and other social protection interventions. Costs and income loss put people with TB at financial risk, requiring mitigation with social protection interventions http://ow.ly/sqgRU ER -